InvestSMART

Emyria Limited (ASX: EMD) - Announcements

Current share price for EMD : $0.044 0.001 (2.22%)+

ASX company news and announcements for Emyria Limited (EMD) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Emyria Limited (EMD) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Emyria Limited (EMD), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Emyria Limited (EMD)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$35 EMD-RX5 program advancing Phase 1 clinical trials underway 17 Mar 2022 9:58AM $0.280 $0.044 fallen by 84.29%
$35 Recruitment commenced for EMD-RX5 Phase 1 Study 9 Mar 2022 9:47AM $0.275 $0.044 fallen by 84%
$35 Hidden Gems Webinar Presentation 4 Mar 2022 10:26AM $0.330 $0.044 fallen by 86.67%
$35 Ethics approval received for EMD-RX5 Phase 1 Study 3 Mar 2022 1:41PM $0.325 $0.044 fallen by 86.46%
$35 Emyria to present at Hidden Gems Webinar March 4th 2 Mar 2022 10:38AM $0.310 $0.044 fallen by 85.81%
$35 Half Yearly Report and Accounts 28 Feb 2022 6:27PM $0.280 $0.044 fallen by 84.29%
$35 Emyria grows its novel MDMA-analogue library 22 Feb 2022 9:53AM $0.270 $0.044 fallen by 83.70%
$35 General Meeting Adjourned - Letter to Shareholders 22 Feb 2022 8:13AM $0.270 $0.044 fallen by 83.70%
$35 Application for quotation of securities - EMD 14 Feb 2022 9:11AM $0.330 $0.044 fallen by 86.67%
$35 Release of securities from escrow 4 Feb 2022 7:28PM $0.340 $0.044 fallen by 87.06%
$35 Notice under section 708A(5)(e) of the Corporations Act 28 Jan 2022 6:48PM $0.375 $0.044 fallen by 88.27%
$35 Application for quotation of securities - EMD 28 Jan 2022 6:44PM $0.375 $0.044 fallen by 88.27%
$35 Appendix 4C - Quarterly 28 Jan 2022 9:52AM $0.360 $0.044 fallen by 87.78%
$35 Letter to Shareholders - General Meeting 21 Jan 2022 6:23PM $0.425 $0.044 fallen by 89.65%
$35 Notice of General Meeting/Proxy Form 21 Jan 2022 6:22PM $0.425 $0.044 fallen by 89.65%
$35 Phase 1 trial commences Q1, 2022 for Emyrias ultra-pure CBD 20 Jan 2022 9:41AM $0.440 $0.044 fallen by 90%
$35 Notification regarding unquoted securities - EMD 31 Dec 2021 3:03PM $0.385 $0.044 fallen by 88.57%
$35 Proposed issue of securities - EMD 30 Dec 2021 10:15AM $0.370 $0.044 fallen by 88.11%
$35 Emyria appoints Sixty Two Capital as corporate advisor 30 Dec 2021 9:57AM $0.365 $0.044 fallen by 87.95%
$35 Notice under section 708A(5)(e) of the Corporations Act 23 Dec 2021 9:52AM $0.335 $0.044 fallen by 86.87%
$35 Application for quotation of securities - EMD 23 Dec 2021 9:49AM $0.335 $0.044 fallen by 86.87%
$35 Change of Registry Address 20 Dec 2021 2:37PM $0.345 $0.044 fallen by 87.25%
$35 Emyria adds wearables to psychedelic-assisted therapy trials 20 Dec 2021 9:10AM $0.370 $0.044 fallen by 88.11%
$35 Trading Halt 16 Dec 2021 10:20AM $0.370 $0.044 fallen by 88.11%
$35 Pause in Trading 16 Dec 2021 9:58AM $0.370 $0.044 fallen by 88.11%

351 - 375 of 557 results

Page 15 of 23

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.